Suppr超能文献

替卡西林加克拉维酸(棒酸噻孢霉素)经胆汁排泄的实验与临床研究

Biliary elimination of ticarcillin plus clavulanic acid (Claventin): experimental and clinical study.

作者信息

Brogard J M, Jehl F, Blickle J F, Adloff M, Dorner M, Montell H

机构信息

Department of Internal Medicine, University Hospital of Strasbourg, France.

出版信息

Int J Clin Pharmacol Ther Toxicol. 1989 Mar;27(3):135-44.

PMID:2722309
Abstract

The aim of the present study was to assess the biliary elimination and disposition of Claventin, a combination of clavulanic acid (CA), a beta-lactamase inhibitor, with ticarcillin (TIC), resulting in an enhancement of the activity of the antibiotic and broadening of its antibacterial spectrum. This work was done experimentally and in humans. Assays of both molecules were performed by HPLC. During a 3 h perfusion of five isolated rabbit liver preparations, 1.3 +/- 0.2% and 0.4 +/- 0.1% of TIC and CA added to the circulating blood were eliminated in the bile. At the same time, 31.8% of TIC and 50.5% of CA were submitted to a hepatic biotransformation. In healthy subjects (n = 5), after a single i.v. injection of 3.2 g of Claventin (TIC: 3 g + CA: 0.2 g) mean peak concentrations of 66.8 +/- 31.9 micrograms/ml (TIC 4th h) and 0.3 +/- 0.1 microgram/ml (CA, 2nd h) were observed in the aspirated duodenal fluid where 0.07% and 0.01%, respectively, of the administered dose were recovered during the 4 h investigation period. In cholecystectomized patients (n = 10) provided with a T-tube, i.v. administration of Claventin, 3.2 g, resulted in biliary maximal levels of 177 +/- 49 micrograms/ml (TIC: 2nd h) and 2.7 +/- 0.5 microgram/ml (CA 1st h). Total amount of each derivative eliminated in bile over 12 h averaged 0.28% (TIC) and 0.05% (CA) of the given dose. Hepatobiliary clearance was 20.5 ml/h (TIC) and 4.4 ml/h (CA). In intra-operative simultaneously sampled specimens of serum, choledochal bile, gallbladder bile and gallbladder wall, the following concentrations were measured 1 h after i.v. administration of Claventin: TIC: 105 +/- 10; 386 +/- 66; 72 +/- 20 micrograms/ml and 36 +/- 11 micrograms/g, CA: 3.5 +/- 0.7; 5.9 +/- 1.5; 0.3 +/- 0.3 microgram/ml and 0.1 +/- 0.1 microgram/g. The biliary pharmacokinetics determined in humans makes it possible to consider favourably the prophylactic use of Claventin in surgery of the biliary tree and constitute a good prerequisite for a possible beneficial treatment of biliary tract infections.

摘要

本研究的目的是评估克拉维汀(一种由β-内酰胺酶抑制剂克拉维酸(CA)与替卡西林(TIC)组成的复方制剂,可增强抗生素活性并拓宽其抗菌谱)的胆汁排泄及处置情况。这项工作通过实验和人体研究完成。两种分子均采用高效液相色谱法进行测定。在对五份离体兔肝制剂进行3小时灌注期间,添加到循环血液中的替卡西林和克拉维酸分别有1.3±0.2%和0.4±0.1%在胆汁中被清除。同时,31.8%的替卡西林和50.5%的克拉维酸发生了肝脏生物转化。在健康受试者(n = 5)中,单次静脉注射3.2克克拉维汀(替卡西林:3克 + 克拉维酸:0.2克)后,在抽取的十二指肠液中观察到平均峰值浓度分别为66.8±31.9微克/毫升(替卡西林,第4小时)和0.3±0.1微克/毫升(克拉维酸,第2小时),在4小时的研究期间,分别回收了给药剂量的0.07%和0.01%。在接受T管引流的胆囊切除患者(n = 10)中,静脉注射3.2克克拉维汀后,胆汁中的最高水平分别为177±49微克/毫升(替卡西林,第2小时)和2.7±0.5微克/毫升(克拉维酸,第1小时)。12小时内胆汁中每种衍生物的总排泄量平均为给药剂量的0.28%(替卡西林)和0.05%(克拉维酸)。肝胆清除率分别为20.5毫升/小时(替卡西林)和4.4毫升/小时(克拉维酸)。在静脉注射克拉维汀1小时后同时采集的术中血清、胆总管胆汁、胆囊胆汁和胆囊壁标本中,测得的浓度如下:替卡西林:105±10;386±66;72±20微克/毫升和36±11微克/克,克拉维酸:3.5±0.7;5.9±1.5;0.3±0.3微克/毫升和0.1±0.1微克/克。在人体中确定的胆汁药代动力学使得在胆道手术中对克拉维汀的预防性使用持乐观态度成为可能,并且为胆道感染的可能有效治疗构成了良好的前提条件。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验